Tauranga, New Zealand: The administration of standardized cannabinoid extracts (Sativex) is safe and effective at mitigating symptoms of Tourettes, according to a case report published online ahead of print in the journal Australasian Psychiatry.
Investigators at the Tauranga Hospital, Department of Psychiatry in New Zealand evaluated the impact of twice-daily Sativex administration in a patient with treatment-resistant Tourette syndrome (TS). Sativex is a spray containing an equal 1:1 ratio of THC to cannabidiol (CBD).
Following treatment, researchers reported an 85 percent reduction in the subject’s motor tics and a 90 percent reduction in vocal tics.
Authors concluded, “Our results support previous research suggesting that cannabinoids are a safe and effective treatment for TS and should be considered in treatment-resistant cases.”
Randomized clinical trials assessing the use of oral THC capsules in patients with TS have similarly reported the treatment to be safe and effective.
For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Severe motor and vocal tics controlled with Sativex,” appears in Australasian Psychiatry. A summary of relevant research specific to cannabis and TS appears online at:http://norml.org/library/item/tourettes-syndrome.